Abstract
The experience with biologicals in currently available animal models suggest that inflammatory autoimmune disease depend on IFN-γ-producing T helper (Th) cells. Deletion of T cells improves most of these autoimmune diseases but bears the risks of general immunosuppression. Alternatively, selective deviation of the inflammatory, disease-inducing Th cells into an anti-inflammatory Th cell phenotype may be a promising strategy to treat inflammatory autoimmune diseases, such as psoriasis, rheumatoid arthritis, multiple sclerosis or autoimmune diabetes. The common feature of these organ-specific autoimmune diseases is the close association with IFN-γ-producing Th1 cells, which recognize organ-specific antigens and orchestrate the cells and mediators that ultimately cause the tissue damage. Even though the autoantigens recognized in psoriasis remain enigmatic, it has been the first Th1-mediated autoimmune disease successfully treated in humans by immune deviation. The basis of such an immune intervention therapy has been established in experimental mice with model diseases of multiple sclerosis, rheumatoid arthritis or autoimmune diabetes. In all these autoimmune diseases clinical improvement was associated with the skewing of IFN-γ producing autoantigenspecific Th1 cells into an IL-4 dominated Th2 phenotype. Such Th2 cells are still reactive to the autoantigen but provide a different cytokine pattern. The most powerful cytokines capable of inducing anti-inflammatory Th2 cells are IL-4 itself or IL-11. Interestingly, another agent that has been used for decades in the therapy of psoriasis in some European countries, fumaric acid esters (FAE), seems also to induce immune deviation. This review focuses on the potential immune deviating strategies based on the use of IL-4, IL-11 or FAE in the therapy of psoriasis, the effects of these agents on the immune system, potential risks and future perspectives for therapeutic intervention by immune deviation replacing immunosuppression.
Keywords: psoriasis, t helper (th) cells, multiple sclerosis, rheumatoid arthritis, autoimmune diabetes
Current Drug Targets - Inflammation & Allergy
Title: Immune Deviation Strategies in the Therapy of Psoriasis
Volume: 3 Issue: 2
Author(s): Kamran Ghoreschi and Martin Rocken
Affiliation:
Keywords: psoriasis, t helper (th) cells, multiple sclerosis, rheumatoid arthritis, autoimmune diabetes
Abstract: The experience with biologicals in currently available animal models suggest that inflammatory autoimmune disease depend on IFN-γ-producing T helper (Th) cells. Deletion of T cells improves most of these autoimmune diseases but bears the risks of general immunosuppression. Alternatively, selective deviation of the inflammatory, disease-inducing Th cells into an anti-inflammatory Th cell phenotype may be a promising strategy to treat inflammatory autoimmune diseases, such as psoriasis, rheumatoid arthritis, multiple sclerosis or autoimmune diabetes. The common feature of these organ-specific autoimmune diseases is the close association with IFN-γ-producing Th1 cells, which recognize organ-specific antigens and orchestrate the cells and mediators that ultimately cause the tissue damage. Even though the autoantigens recognized in psoriasis remain enigmatic, it has been the first Th1-mediated autoimmune disease successfully treated in humans by immune deviation. The basis of such an immune intervention therapy has been established in experimental mice with model diseases of multiple sclerosis, rheumatoid arthritis or autoimmune diabetes. In all these autoimmune diseases clinical improvement was associated with the skewing of IFN-γ producing autoantigenspecific Th1 cells into an IL-4 dominated Th2 phenotype. Such Th2 cells are still reactive to the autoantigen but provide a different cytokine pattern. The most powerful cytokines capable of inducing anti-inflammatory Th2 cells are IL-4 itself or IL-11. Interestingly, another agent that has been used for decades in the therapy of psoriasis in some European countries, fumaric acid esters (FAE), seems also to induce immune deviation. This review focuses on the potential immune deviating strategies based on the use of IL-4, IL-11 or FAE in the therapy of psoriasis, the effects of these agents on the immune system, potential risks and future perspectives for therapeutic intervention by immune deviation replacing immunosuppression.
Export Options
About this article
Cite this article as:
Ghoreschi Kamran and Rocken Martin, Immune Deviation Strategies in the Therapy of Psoriasis, Current Drug Targets - Inflammation & Allergy 2004; 3 (2) . https://dx.doi.org/10.2174/1568010043343949
DOI https://dx.doi.org/10.2174/1568010043343949 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design Design, Synthesis and Evaluation of Chalcone Derivatives as Anti- Inflammatory, Antioxidant and Antiulcer Agents
Letters in Drug Design & Discovery Mediterranean Diet and Osteoarticular Diseases
Current Nutrition & Food Science B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Current Pharmaceutical Design Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Fabrication, In vitro and In vivo Characterization of Solid Dispersion- Microsphere Controlled Release System for Lornoxicam
Nanoscience & Nanotechnology-Asia Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Anti Cancer Activity on Graviola, an Exciting Medicinal Plant Extract vs Various Cancer Cell Lines and a Detailed Computational Study on its Potent Anti-Cancerous Leads
Current Topics in Medicinal Chemistry STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis
Mini-Reviews in Medicinal Chemistry Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design Brittle Asthma
Current Respiratory Medicine Reviews Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets The Prevalence of Frailty in Patients Admitted to Hospital with Vertebral Fragility Fractures
Current Rheumatology Reviews Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology